The Ambulight PDT by Ambicare Health was officially unveiled today (12 March) to key European practitioners at The European Society for Photodynamic Therapy (‘Society’ or ‘Euro-PDT’) 10th Annual Congress in Monte-Carlo, Monaco.
The Euro-PDT is one of Europe’s most prestigious conferences for new developments and research in all aspects of PDT for skin diseases, the Ambulight PDT will be showcased to members of the Society from all across Europe.
Having received CE Mark approval last year enabling active marketing of the device in Europe, the conference will give Dr Andrew McNeill, Director and Principle Scientist of Ambicare Health the opportunity to present the company’s research for the first time on ‘Ambulatory light sources for PDT’.
Ambulight PDT is the world’s first skin cancer treatment using a small disposable light emitting sticking plaster worn by the patient. This is used in conjunction with a prescribed pharmaceutical, for the treatment of non-melanoma skin cancer. This plaster delivers PDT treatment directly to the skin lesion site.
Ambulight PDT offers healthcare providers the opportunity to transform patient care by making PDT more accessible and enabling patients to continue with their normal daily routine when undergoing PDT treatment. Pilot clinical trials have also indicated this treatment method has lower pain than conventional techniques whilst still obtaining an equivalent outcome.
Ian Muirhead, CEO of Ambicare Health said, “The Ambulight PDT is the most advanced ambulatory PDT device to treat non-melanoma skin cancer to be developed to date. We believe that it is the future for this kind of treatment; Ambulight PDT will reduce costs for the healthcare provider by freeing up hospital day patient beds or cubicles and improve patient care by allowing them to continue with their normal daily lives during treatment.
“The Euro-PDT congress is an important platform for us to demonstrate the technology and research that has been years in the development and to further emphasis the benefits this revolutionary product could bring to a global market.”
